argenex SE (NASDAQ:ARGX) Receives Consensus Rating of “Moderate Buy” from Analysts

argenex SE (NASDAQ:ARGX) has been assigned a consensus rating of “Moderate Buy” from the twenty-six ratings firms that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $982.3333.

ARGX has been the subject of a number of research reports. Piper Sandler lifted their price objective on shares of argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. HC Wainwright raised their price target on shares of argenex from $774.00 to $915.00 and gave the company a “buy” rating in a research report on Friday, October 31st. JPMorgan Chase & Co. boosted their price target on shares of argenex from $925.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Monday, December 8th. Robert W. Baird restated a “neutral” rating and set a $858.00 price target (down previously from $924.00) on shares of argenex in a report on Thursday, December 18th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th.

Institutional Investors Weigh In On argenex

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Ameriflex Group Inc. purchased a new stake in shares of argenex during the 3rd quarter worth $32,000. Sunbelt Securities Inc. purchased a new position in argenex in the third quarter valued at $36,000. Bessemer Group Inc. raised its stake in argenex by 276.5% in the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock valued at $47,000 after buying an additional 47 shares in the last quarter. MAI Capital Management lifted its holdings in argenex by 866.7% during the 2nd quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after buying an additional 78 shares during the last quarter. Finally, Mather Group LLC. acquired a new position in shares of argenex during the 3rd quarter worth about $50,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Trading Up 0.4%

ARGX stock opened at $840.95 on Friday. The business’s fifty day moving average price is $872.49 and its 200 day moving average price is $742.33. argenex has a 12-month low of $510.05 and a 12-month high of $934.62. The company has a market capitalization of $51.78 billion, a PE ratio of 36.11, a P/E/G ratio of 0.87 and a beta of 0.38.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating analysts’ consensus estimates of $4.37 by $0.03. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. Research analysts predict that argenex will post 3.13 EPS for the current fiscal year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.